Glucagon-like peptide-1 (GLP-1) receptor agonists are an increasingly important class of medicines in the global pharmaceutical and healthcare industries. Initially developed to support the management of type 2 diabetes, these therapies have attracted wider clinical and commercial attention because of their effects on blood glucose regulation, appetite signalling, and metabolic processes....